In recent years, viral vector gene therapies reentered the advanced modality spotlight, offering transformational potential for patients in high morbidity or mortality indications with significant unmet medical need. While the field has experienced several setbacks related to safety and efficacy, the global pipeline continues to experience significant growth.

In order for this pipeline to translate into marketed therapies, the field will need to address eight key challenges within two broad categories: 1) gene therapy design, or what is made, and 2) the manufacturing process, or how it is made. In this special report, L.E.K. Consulting reviews these challenges and the bioprocessing solutions that could shape the trajectory of the viral-based gene therapy landscape. 

Related Insights